Pharma competitive intelligence FAQ

RxClarity is an AI pharma competitive intelligence platform for research, strategy, and growth teams. It monitors drug pipelines, clinical trials, regulatory activity, patent cliffs, market news, and competitors across therapy areas.

Teams define the companies, assets, indications, targets, and market signals that matter. RxClarity continuously screens for relevant change, connects it to market context, and links outputs to their underlying sources.

General AI tools can search and summarise information, but they do not maintain a live, structured view of your pharmaceutical market.

RxClarity combines a curated pharma database, specialist mapping processes, pharma-specific intelligence rules, continuous monitoring, and source-linked AI agents. You can build agents around your own context and run prompts or workflows on demand or on a schedule.

The outcome: a current view of what changed, why it matters, and what may require attention—without rebuilding the research scope every time.

RxClarity monitors relevant activity across:

Monitoring is shaped by your focus, so teams receive intelligence relevant to their markets rather than broad, generic alerts.

Yes. RxClarity helps teams track competitor assets and identify relevant pipeline developments, including new programmes, phase progression, trial-status changes, data disclosures, programme reprioritisation, and reported discontinuations.

Each update is connected to the relevant company, asset, indication, trial, and source evidence where available.

Yes. You can create prompts and proactive workflows around the questions your team repeatedly asks.

For example:

Agents read your defined context and can run analysis on demand or on a schedule.

RxClarity surfaces known and inferred milestones that may affect a market, including clinical-trial completion dates, potential readout windows, regulatory events, patent expiries, and competitor development milestones.

These are forward-looking monitoring signals, not predictions of clinical, regulatory, or commercial outcomes.

Accuracy and traceability are core product priorities. RxClarity grounds outputs in a curated database and applies pharma-specific rules to entity mapping, monitoring, and evidence linking.

Every output is designed to be reviewable, with links back to relevant source records such as clinical trials, drugs, companies, regulatory applications, publications, patents, and news.

RxClarity accelerates research; it does not replace clinical, scientific, legal, or strategic judgment.

RxClarity includes multi-regional studies conducted in China and trials from Chinese sponsors seeking international visibility.

Coverage of domestic studies registered only on the Chinese Clinical Trial Registry (ChiCTR) is planned for a future release.

Yes. Teams can export analyses and underlying records for internal presentations, reports, and models. API access is also available for integrating RxClarity intelligence into existing workflows and internal tools.

Packages start from $10,000 per year and include the RxClarity dashboard, chat agent, and custom agents. Early customers receive a 50% discount.

Yes. If you need a specific analysis, landscape, benchmark, or workflow, contact the team with your requirements.

Yes. RxClarity is open to partnerships with healthcare-focused consultancies and investors.